In the last trading session, 2.03 million shares of the Regenxbio Inc (NASDAQ:RGNX) were traded, and its beta was 1.23. Most recently the company’s share price was $9.56, and it changed around -$0.59 or -5.81% from the last close, which brings the market valuation of the company to $473.65M. RGNX currently trades at a discount to its 52-week high of $28.80, offering almost -201.26% off that amount. The share price’s 52-week low was $8.53, which indicates that the current value has risen by an impressive 10.77% since then. We note from Regenxbio Inc’s average daily trading volume that its 10-day average is 1.14 million shares, with the 3-month average coming to 587.76K.
Regenxbio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.27. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 1 recommended RGNX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Regenxbio Inc is expected to report earnings per share of -1.12 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Regenxbio Inc (NASDAQ:RGNX) trade information
Instantly RGNX has showed a red trend with a performance of -5.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 12.11 on recent trading dayincreased the stock’s daily price by 21.06%. The company’s shares are currently down -46.74% year-to-date, but still down -8.87% over the last five days. On the other hand, Regenxbio Inc (NASDAQ:RGNX) is -7.81% down in the 30-day period. We can see from the shorts that 4.91 million shares have been sold at a short interest cover period of 9.78 day(s).
The consensus price target as assigned by Wall Street analysts is $36.5, which translates to bulls needing to increase their stock price by 73.81% from its current value. Analyst projections state that RGNX is forecast to be at a low of $18 and a high of $40.
Regenxbio Inc (RGNX) estimates and forecasts
Regenxbio Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -37.64 percent over the past six months and at a 19.27% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 21.76% in revenue this quarter, and will report an increase of 18.96% in the next quarter. The year-over-year growth rate is expected to be -3.73%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 23.45M in revenue for the current quarter. 6 analysts expect Regenxbio Inc to make 20.54M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 22.21M and 15.62M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5.56%. Forecasts for the next quarter put sales growth at 31.49%.
Regenxbio Inc earnings are expected to increase by 21.64% in 2024, but the outlook is positive 13.60% per year for the next five years.
RGNX Dividends
Regenxbio Inc’s next quarterly earnings report is expected to be released in December.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 7.39% of Regenxbio Inc shares, and 92.25% of them are in the hands of institutional investors. The stock currently has a share float of 99.62%. Regenxbio Inc stock is held by 272.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 18.8252% of the shares, which is about 8.61 million shares worth $100.73 million.
VANGUARD GROUP INC, with 11.1818% or 5.11 million shares worth $59.83 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
